Expand IMMX Menu
IMMX MENU

IMMX Latest Press Releases

-- December 9, 2025 --

Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants Globe Newswire 5:45 PM

-- December 7, 2025 --

Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants Globe Newswire 6:20 PM
At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis Globe Newswire 6:15 PM

-- November 12, 2025 --

Immix Biopharma Appoints Chief Commercial Officer to Drive NXC-201 Launch Globe Newswire 8:45 AM

-- November 3, 2025 --

Immix Biopharma's NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at ASH 2025 Globe Newswire 8:45 AM

-- October 14, 2025 --

Immix Biopharma to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference Globe Newswire 8:45 AM

-- October 6, 2025 --

Immix Biopharma to Present Abstract at the upcoming ASH 2025 Annual Meeting Globe Newswire 4:05 PM

-- October 1, 2025 --

Immix Biopharma to Present at the 37th Annual Piper Sandler Healthcare Conference Globe Newswire 8:45 AM

-- September 18, 2025 --

Immix Biopharma Announces 50% Enrollment Milestone Surpassed in its ongoing relapsed/refractory AL Amyloidosis Clinical Trial, NEXICART-2 Globe Newswire 1:30 PM

-- September 11, 2025 --

Nancy T. Chang, Proven Biotechnology Leader, Joins Immix Biopharma Board of Directors Globe Newswire 9:15 AM

-- September 8, 2025 --

Immix Biopharma Announces Strategic Investment by Houston based Goose Capital, led by founding member Dr. Nancy T. Chang Globe Newswire 4:05 PM

-- August 25, 2025 --

Immix Biopharma to Present at the Stifel 2025 Healthcare Conference Globe Newswire 9:30 AM

-- August 6, 2025 --

Immix Biopharma Announces Other Serious Diseases Strategy Globe Newswire 12:30 PM
Market Data Delayed 15 Minutes